

12 AUG 1 0 2007					
THE THE DEMARK OF THE	U.S. DEPARTMENT OF C	OMMERCE	ě		
TRADEMARK OT	PATENT AND TRADEMARK OFFICE				
SUPPLEMEN	SUPPLEMENTAL INFORMATION Docket Number:				
DISCLOSURE STATEMENT		1662/79802			
Application Number	Filing Date	Examiner	Art Unit		
10/823,802	April 12, 2004	S. T. Tran	1615		
Invention Title		Inventors			
FORMULATIONS	OF AMLODIPINE MALEATE	Gabor Pragai et al.			

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop: Amendment, Commissioner for Patents, P.O. Box

1450, Alexandria, VA 22313-1450 on

Signature:

Sharon T. Huang

Sir:

Pursuant to 37 CFR § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). The paragraphs marked below are applicable. It is believed that no fees other than those indicated below are due, but authorization is hereby given to charge any additional fees due, or to credit any overpayment, to Kenyon & Kenyon LLP, deposit account 11-0600.

- This Information Disclosure Statement is being filed (a) within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. §1.53(d), (b) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, (c) before the mailing date of a first Office Action on the merits in the present application, OR (d) before the mailing of a first office action after filing of a request for continued examination. No certification or fee is required.
- × This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits. but before the mailing date of a final action, Notice of Allowance, or any action that otherwise closes prosecution.
 - I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).

08/10/2007 WASFAW1 00000011 110600 10823802

01 FC:1806

180.00 DA

co wa	I hereby certify that no item of information in this Information isclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, as known to any individual designated in 37 CFR §1.56(c) more than three months rior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
co	c. Please debit Kenyon & Kenyon LLP , Deposit Account No. 11-0600 the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p) to ensure onsideration of the disclosed information. Two duplicate copies of this paper are tached. 37 CFR §1.97(c)(2).
payment of Statement 0600 in the	This Information Disclosure Statement is being filed after the mailing date of a con, Notice of Allowance or an action that otherwise closes prosecution, but before of the Issue Fee. Applicant(s) hereby request(s) that the Information Disclosure t be considered. Please debit Kenyon & Kenyon LLP , Deposit Account No. 11 -he amount of \$180.00 in payment of the petition fee under 37 CFR §1.17(p) to ensideration of the disclosed information. Two duplicate copies of this paper are
pa	a. I hereby certify that each item of information contained in this aformation Disclosure Statement was first cited in a communication from a foreign atent office in any counterpart foreign application not more than three months prior the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
co	b. I hereby certify that no item of information in this Information isclosure Statement was cited in a communication from a foreign patent office in a punterpart foreign application or, to my knowledge after making reasonable inquiry, as known to any individual designated in 37 CFR §1.56(c) more than three months from to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
4. specificat	Free Process (1) 11 11 11 11 11 11 11 11 11 11 11 11 1
	The references were cited in office actions in counterpart foreign applications. language version of the foreign corresponding foreign office actions and responses re attached for the Examiner's information.
6. reference	A concise explanation of the relevance of the non-English language (s) appears in the Appendix attached hereto.
application respectful	The Examiner's attention is directed to co-pending U.S. Patent Application No
	This application is one of a series of related applications, identified below, e directed to related technical subject matter. The identification of those U.S. Patent ons is not to be construed as a waiver of secrecy as to those applications now or

upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during the examination.
9. The reference(s) was/were cited by or submitted to the Office in parent application No, filed, which is relied upon for an earlier filing date under 35 U.S.C. §120. Thus, copies of these references are not attached. 37 CFR §1.98(d).
☐ 10. English-language Abstracts of the non-English language references are attached hereto.
☐ 11. Since this application was filed after June 30, 2003, copies of U.S. references are not included.
12. Other. The references cited herein were cited in an International Search Report of PCT/US2004/011642 provided herewith.
Respectfully submitted,
Date: AUGUST 7, 2007 Joseph A. Coppola (Reg. No. 38,413)
KENYON & KENYON LLP

Substitute for form 1449A/PTO	Complete if Known		
SUPPLEMENTAL	Application Number	10/823,802	
INFORMATION DISCLOSURE	Filing Date	April 12, 2004	
STATEMENT BY APPLICANT	First Named Inventor	Gabor Pragai et al.	
	Art Unit	1615	
(Use as many sheets as necessary)	Examiner Name	Susan T. Tran	

1662/79802 Attorney Docket Number

	U.S. PATENT DOCUMENTS							
Xaminer Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		Number - Kind Code ² (if known)						
İ								
ł								
İ								
ŀ								

FOREIGN PATENT DOCUMENTS						
	Cite No. ¹	Foreign Patent Document		Mana of Batantas as	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Examiner Initials*		Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		T [®]
	•	EP 0 089 167	10-15-1986	Campbell et al.		
		EP 1 266 654	12-18-2002	Bilotte et al.		
		EP 1 435 239	07-07-2004	Seth		

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				
		A. P. Beresford et al. "Metabolism and kinetics of amlodipine in man" Xenobiotica, Vol. 18, No. 2, pp. 245-254 (1988)			
		·			
		·			

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation

if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.